Positive effect of Actinium 225-PSMA treatment on ECOG performance status: A case report on a patient with castration resistant stage IV prostate carcinoma

Rev Esp Med Nucl Imagen Mol (Engl Ed). 2019 Jul-Aug;38(4):260-261. doi: 10.1016/j.remn.2018.09.003. Epub 2019 Jan 18.

[Article in English, Spanish]

Authors

F Novruzov¹, J A Aliyev², Z Allahverdiyeva³, E Mehdi¹, F Giammarile⁴

Affiliations

¹ Department of Nuclear Medicine, National Centre of Oncology, Baku, Azerbaiyán.
² Department of General Surgery, National Centre of Oncology, Baku, Azerbaiyán.
³ Department of Medical Oncology, Central Clinic Hospital, Baku, Azerbaiyán.
⁴ International Atomic Energy Agency, Nuclear Medicine and Diagnostic Imaging Section, Viena, Austria. Electronic address: F.Giammarile@iaea.org.

PMID: 30665750
DOI: 10.1016/j.remn.2018.09.003

No abstract available

Publication types

Case Reports

MeSH terms

Actinium / therapeutic use*
Antigens, Surface / therapeutic use
Glutamate Carboxypeptidase II / therapeutic use
Humans
Male
Neoplasm Staging
Prostatic Neoplasms, Castration-Resistant / pathology
Prostatic Neoplasms, Castration-Resistant / radiotherapy*
Treatment Outcome

Substances

Actinium-225
Antigens, Surface
FOLH1 protein, human
Glutamate Carboxypeptidase II
Actinium